VRCA Stock Price, Verrica Pharmaceuticals Quote, Chart

Market Summary

USD8.68-0.47

Market Closed

-5.14%

VRCA Stock Price

View Fullscreen

VRCA RSI Chart

VRCA Valuation

Market Cap

368.2M

Price/Earnings (Trailing)

-4.56

Price/Sales (Trailing)

41.31

Price/Free Cashflow

-6.78

VRCA Price/Sales (Trailing)

VRCA Profitability

Return on Equity

-5.4K%

Return on Assets

-121.76%

Free Cashflow Yield

-14.74%

VRCA Fundamentals

VRCA Revenue

Revenue (TTM)

8.9M

Rev. Growth (Yr)

3.0K%

Rev. Growth (Qtr)

92.45%

VRCA Earnings

Earnings (TTM)

-80.7M

Earnings Growth (Yr)

-208.56%

Earnings Growth (Qtr)

17.4%

Breaking Down VRCA Revenue

Last 7 days

8.5%

Last 30 days

23.0%

Last 90 days

59.3%

Trailing 12 Months

46.4%

How does VRCA drawdown profile look like?

VRCA Financial Health

Current Ratio

3.17

Debt/Equity

28.41

Debt/Cashflow

-1.26

VRCA Investor Care

Shares Dilution (1Y)

1.10%

Diluted EPS (TTM)

-1.77

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	8.9M	0	0	0
2023	8.1M	7.1M	6.1M	5.1M
2022	11.3M	10.5M	9.8M	9.0M
2021	0	0	0	12.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Verrica Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 15, 2024	hayes christopher g.	acquired	-	-	40,000	chief legal officer
Mar 15, 2024	goldenberg gary	acquired	-	-	40,000	chief medical officer
Mar 15, 2024	bonaccorso joe	acquired	-	-	40,000	chief commercial officer
Mar 15, 2024	kohler terry	acquired	-	-	40,000	chief financial officer
Mar 15, 2024	white ted	acquired	-	-	112,500	president and ceo
Dec 29, 2023	perceptive advisors llc	bought	838,204	7.24	115,774	-
Dec 28, 2023	perceptive advisors llc	bought	892,901	7.08	126,116	-
Dec 27, 2023	perceptive advisors llc	bought	574,027	7.2	79,726	-
Dec 26, 2023	perceptive advisors llc	bought	354,691	6.49	54,652	-
Dec 22, 2023	perceptive advisors llc	bought	1,667,500	6.67	250,000	-

Which funds bought or sold VRCA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-74,854	-	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.91	-12,726	12,426	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	new	-	115,766	115,766	-%
May 15, 2024	DEUTSCHE BANK AG\	added	114	460,517	1,086,760	-%
May 15, 2024	STATE STREET CORP	added	5.99	-406,824	2,442,610	-%
May 15, 2024	WELLINGTON MANAGEMENT GROUP LLP	new	-	606,119	606,119	-%
May 15, 2024	MORGAN STANLEY	added	20.58	-20,195	794,558	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-26.48	-108,849	159,656	-%
May 15, 2024	BARCLAYS PLC	reduced	-49.04	-124,000	86,000	-%
May 15, 2024	Avoro Capital Advisors LLC	unchanged	-	-5,600,000	23,680,000	0.28%

Are Funds Buying or Selling VRCA?

Are funds buying VRCA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VRCA

No. of Funds

Unveiling Verrica Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	perceptive advisors llc	16.9%	7,099,182	SC 13G/A
Feb 14, 2024	avoro capital advisors llc	9.99%	6,583,332	SC 13G
Feb 14, 2023	perceptive advisors llc	12.3%	5,038,983	SC 13G/A
Jul 15, 2022	manning paul b	37.4%	15,389,481	SC 13D
Feb 14, 2022	manning paul b	38.6%	10,627,577	SC 13G/A
Feb 14, 2022	perceptive advisors llc	13.1%	3,610,412	SC 13G/A
Feb 11, 2022	orbimed advisors llc	0.00%	0	SC 13G/A
Jan 27, 2022	davidson matt	2.04%	560,731	SC 13G/A
Feb 17, 2021	perceptive advisors llc	13.2%	3,410,412	SC 13G/A
Feb 16, 2021	manning paul b	38.0%	9,837,747	SC 13G/A

Recent SEC filings of Verrica Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	8-K	Current Report
May 13, 2024	S-8	Employee Benefits Plan
May 13, 2024	8-K	Current Report
May 13, 2024	10-Q	Quarterly Report
Apr 19, 2024	DEFA14A	DEFA14A
Apr 19, 2024	DEF 14A	DEF 14A
Apr 19, 2024	ARS	ARS
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading

Peers (Alternatives to Verrica Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Verrica Pharmaceuticals Inc News

Latest updates

Verrica Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)													(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1
Revenue	92.5%	3,826	1,988	2,917	182	125	68.00	8,319	5,546	2,773	-	-	-	12,000
Operating Expenses	-10.7%	22,425	25,125	26,834	11,798	7,126	6,280	6,871	9,335	7,841	8,470	11,768	10,731	11,940
S&GA Expenses	-3.9%	16,339	16,995	20,054	5,937	4,319	3,189	3,925	5,173	5,118	5,113	8,005	7,284	6,578
R&D Expenses	-7.0%	4,948	5,320	6,510	5,725	2,739	3,029	2,780	3,943	2,445	3,357	3,763	3,447	5,362
Interest Expenses	-20.3%	1,836	2,305	1,657	-	-	-28.50	81.00	1,066	1,082	1,098	1,092	1,077	1,028
Net Income	17.4%	-20,331	-24,614	-24,802	-10,990	-6,589	-5,932	83.00	-10,168	-8,470	-9,540	-12,829	-11,775	-936
Net Income Margin	30.7%	-9.06*	-13.07*	-7.92*	-3.31*	-2.81*	-2.71*	-2.87*	-3.90*	-3.79*	-2.92*	-	-	-
Free Cashflow	-35.4%	-19,947	-14,734	-14,876	-4,728	-4,601	-5,020	1,748	-7,335	-8,345	-8,935	-10,637	2,203	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-18.7%	66.00	82.00	97.00	62.00	69.00	45.00	49.00	63.00	72.00	80.00	89.00	99.00	108	74.00	80.00	87.00	94.00	68.00	76.00	81.00	86.00
Current Assets	-20.8%	61.00	78.00	92.00	57.00	63.00	39.00	43.00	57.00	66.00	74.00	83.00	93.00	102	68.00	74.00	83.00	91.00	65.00	74.00	80.00	85.00
Cash Equivalents	-29.6%	49.00	70.00	84.00	55.00	60.00	34.00	32.00	45.00	50.00	16.00	20.00	25.00	44.00	11.00	17.00	49.00	54.00	9.00	11.00	20.00	24.00
Inventory	144.5%	2.00	1.00	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net PPE	-10.9%	1.00	1.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	3.00	3.00	3.00	3.00	2.00	2.00	2.00	1.00	1.00
Liabilities	4.8%	65.00	62.00	55.00	7.00	4.00	5.00	4.00	47.00	46.00	48.00	48.00	47.00	46.00	41.00	41.00	39.00	38.00	3.00	4.00	4.00	3.00
Current Liabilities	13.8%	19.00	17.00	11.00	6.00	3.00	3.00	3.00	46.00	45.00	46.00	46.00	45.00	45.00	39.00	39.00	39.00	3.00	3.00	4.00	4.00	3.00
Short Term Borrowings	-	-	-	-	-	-	-	-	42.00	42.00	42.00	41.00	41.00	-	35.00	-	-	-	-	-	-	-
Long Term Debt	-0.1%	43.00	43.00	42.00	-	-	-	-	-	-	-	-	-	-	-	-	-	34.00	-	-	-	-
Shareholder's Equity	-92.4%	2.00	20.00	42.00	55.00	65.00	40.00	45.00	16.00	25.00	33.00	41.00	52.00	62.00	33.00	39.00	48.00	57.00	65.00	72.00	77.00	83.00
Retained Earnings	-8.8%	-250	-230	-205	-181	-170	-163	-157	-157	-147	-138	-129	-116	-104	-103	-90.90	-80.40	-71.01	-61.19	-53.55	-47.46	-40.46
Additional Paid-In Capital	0.8%	252	250	248	236	235	203	202	174	173	172	170	169	167	137	131	129	128	127	125	124	123
Shares Outstanding	0.0%	42.00	42.00	42.00	42.00	42.00	41.00	32.00	28.00	28.00	28.00	28.00	28.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	152	-	-	-	32.00	-	-	-	186	-	-	-	173	-	-	-	181	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-37.5%	-19,947	-14,507	-14,811	-4,669	-4,590	-4,954	1,825	-7,181	-8,340	-8,698	-10,598	2,499	-10,785	-6,099	-7,608	-8,594	-7,906	-8,213	-7,228	-5,050	-6,917
Share Based Compensation	-100.0%	-	2,075	9,663	1,544	1,094	1,171	1,413	1,085	1,316	1,321	1,481	1,848	1,403	6,340	1,231	1,252	998	802	905	846	780
Cashflow From Investing	100.0%	-	-227	-65.00	-59.00	-11.00	6,754	2,069	2,205	43,013	4,011	6,291	-22,135	10,835	-858	-24,126	3,130	18,274	6,650	-2,028	263	21,070
Cashflow From Financing	-2348.1%	-661	-27.00	44,044	-84.00	30,280	-	-16,851	-1.00	-18.00	-3.00	43.00	241	33,365	445	-	-90.00	34,877	204	4.00	212	3.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

VRCA Income Statement

2024-03-31

STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues [Abstract]
Total revenue	$ 3,826	$ 37
Operating expenses:
Selling, general and administrative	16,339	4,319
Research and development	4,948	2,739
Cost of product revenue	546	0
Cost of collaboration revenue	592	68
Total operating expenses	22,425	7,126
Loss from operations	(18,599)	(7,089)
Other (expense) income:
Interest income	598	500
Interest expense	(2,319)	0
Other expense	(11)	0
Total other (expense) income, net	(1,732)	500
Net loss	$ (20,331)	$ (6,589)
Net loss per share, basic	$ (0.44)	$ (0.15)
Net loss per share, diluted	$ (0.44)	$ (0.15)
Weighted-average common shares outstanding, basic	46,483,669	43,023,379
Weighted-average common shares outstanding, diluted	46,483,669	43,023,379
Product [Member]
Revenues [Abstract]
Total revenue	$ 3,232	$ 0
Collaboration [Member]
Revenues [Abstract]
Total revenue	$ 594	$ 37

VRCA Balance Sheet

2024-03-31

BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 48,939	$ 69,547
Accounts receivable, net	7,002	4,248
Unbilled revenue receivable	592	168
Inventory	2,499	1,022
Prepaid expenses and other assets	2,344	2,545
Total current assets	61,376	77,530
Property and equipment, net	937	1,052
Operating lease right-of-use asset	1,082	1,158
Finance lease right-of-use asset	2,460	1,405
Other non-current assets	452	452
Total assets	66,307	81,597
Current liabilities:
Accounts payable	2,527	2,464
Accrued expenses and other current liabilities	15,828	13,860
Operating lease liability	331	324
Financing lease liability	679	376
Total current liabilities	19,365	17,024
Operating lease liability	825	910
Financing lease liability	1,761	1,026
Long term debt	42,848	42,874
Total liabilities	64,799	61,834
Commitments and Contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of March 31, 2024 and December 31, 2023	0	0
Common stock, $0.0001 par value; 200,000,000 authorized; 42,525,197 shares issued and 42,420,053 shares outstanding as of March 31, 2024 and 42,518,697 shares issued and 42,413,553 shares outstanding as of December 31, 2023	4	4
Treasury stock, at cost, 105,144 shares as of March 31, 2024 and December 31, 2023	0	0
Additional paid-in capital	252,287	250,207
Subscription receivable	(4)	0
Accumulated deficit	(250,779)	(230,448)
Total stockholders’ equity	1,508	19,763
Total liabilities and stockholders’ equity	$ 66,307	$ 81,597

About Verrica Pharmaceuticals Inc

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing VP-315, an oncolytic peptide-based injectable therapy for the treatment of dermatology oncologic conditions, including basal cell carcinoma; and cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, including non-metastatic melanoma and non-metastatic Merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

CEO	Mr. Ted White
WEBSITE	verrica.com
INDUSTRY	Biotechnology
EMPLOYEES	22

Verrica Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Verrica Pharmaceuticals Inc? What does VRCA stand for in stocks?

VRCA is the stock ticker symbol of Verrica Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Verrica Pharmaceuticals Inc (VRCA)?

As of Fri May 17 2024, market cap of Verrica Pharmaceuticals Inc is 368.21 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VRCA stock?

You can check VRCA's fair value in chart for subscribers.

What is the fair value of VRCA stock?

You can check VRCA's fair value in chart for subscribers. The fair value of Verrica Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Verrica Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VRCA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Verrica Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether VRCA is over valued or under valued. Whether Verrica Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Verrica Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VRCA.

What is Verrica Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, VRCA's PE ratio (Price to Earnings) is -4.56 and Price to Sales (PS) ratio is 41.31. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VRCA PE ratio will change depending on the future growth rate expectations of investors.